Every SEC filing of 1,372 US microcaps, read every morning.
Who is about to be forced to sell stock, who is about to lose their listing, who just got a first going-concern flag or restatement, and where insiders are buying — stitched into setups with explicit what would confirm / what would prove us wrong. Every item links to the filing. Updated Aug 16, 2026 · 06:15 ET weekdays · SEC EDGAR · research, not advice.
Choose what you're looking for. Pressure ▼ = supply and survival risk for existing holders (dilution, listing, going concern, reporting). Support ▲ = insiders and large holders putting money in. Top 5 of 985 flagged companies free; Pro sees all of them. Screener →
Radar 0–100 = how much is happening × how much it matters (attention, not direction)Pressure ▼ negative for existing holdersSupport ▲ insiders/holders buyingMixed ◆ both present<40 low · 40–69 elevated · 70+ highWhat do these numbers mean? →
Ranked by Radar. Dilution, Listing, Governance are the Radar score restricted to those categories; open a ticker for the bottom line, the setups and every filing.
Ranked by Support (open-market insider buys, 10% holder buys, new 13D filers). Read Support next to runway and dilution: insiders buying while a raise is coming is a different setup from insiders buying alone — those rows show Mixed ◆.
284 setups across 985 flagged companies · 5 full analyst notes · the CSV · same-day
Free shows the top 5 per tab and the headline of each note. Pro shows everything, the morning it happens, plus watchlist alerts so you don't have to look. Read a complete Pro morning →
On August 12–14, 2026, Outlook Therapeutics (OTLK) completed a $55.0 million public offering at $0.99 per share-plus-warrant unit (55,555,556 shares) for net proceeds of ~$51.1 million. The offering closed shortly after the July 24, 2026 FDA approval of LYTENA…
BOXABL Inc. (formerly FG Merger II Corp.) closed its SPAC merger on July 17, 2026, converting from Nevada to Texas and issuing 246.5 million common shares plus 103.5 million preferred shares at a $3.5 billion valuation. On July 23, 2026, the company filed an 8…
VivoSim Labs received a Nasdaq notice on July 24, 2026, stating it failed to maintain the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1), based on its March 31, 2026 fiscal year-end equity deficit of $(1.1) million. The com…
On August 14, 2026, HCW Biologics filed an Item 4.02 non-reliance 8-K announcing that its Q1 2026 earnings-per-share calculation was materially misstated due to incorrect application of the two-class method for participating warrants; reported EPS of $2.19 ove…
Cycurion (CYCU) closed an Aug. 3 warrant inducement transaction that generated $4.5M gross proceeds by inducing immediate exercise of Dec. 2025 warrants for 3.3M shares at $1.35/share (reduced from $3.62) – a 63% discount to the $3.62 original strike. As consi…
1,372companies monitored
4,242signals, last 30 days
387multi-filing setups
285companies with < 6 months cash
428companies with < 12 months cash
How to use it
BEFORE YOU BUY A MICROCAPCheck the ticker page firstDilution pressure, months of cash, listing risk and whether an ATM or equity line is live. Most microcap losses come from supply, not from the story being wrong. Search any ticker in the top bar.
TRADE THE SETUPSPressure ▼ setups have datable next stepsA forced raise ends in a 424B; a listing cliff ends in a reverse split or a Form 25. Each setup lists what would confirm and what would prove it wrong, so you know what to watch and when you're wrong.
FOLLOW THE MONEYSupport ▲ is rare and worth readingInsider buying clusters and new 13D filers in distressed names are the closest thing to a conviction signal in filings. Cross-check with runway: conviction plus a raise coming is a very different setup from conviction alone.
DAILY IN 3 MINUTESRead the top table, then "what changed"New going-concern flags, delisting notices and restatements are same-day; the table ranks who has the most going on. Pro adds the full list, the screener, alerts and the analyst notes.
How it works
1 · READEvery filing, every morning8-Ks by item code, S-1/S-3/424B, NT filings, 13D, Form 4, XBRL cash and burn, plus full-text refinement queries across the whole universe.
2 · SCOREImportance × novelty × confidence × magnitudeA boilerplate phrase can never outrank a hard 8-K item; a first-ever event outranks the fifth; stale balance sheets lose confidence.
3 · CONNECTFilings become setupsCash need + live selling machinery = forced raise. Deficiency notice + no easy cure = listing cliff. Each with confirm / invalidate criteria.
4 · RED-TEAMAnalyst note, then a skeptic tries to break itUnsupported claims, bad runway math, boilerplate mistaken for a going concern — flagged or killed before anything is published.
Free: morning digest, top-10 setups, every ticker page. Pro ($29/mo — founding rate $18.85/mo, 35% off forever until Sept 30): full same-day screener + CSV, all analyst notes, watchlist alerts, 12-month history. See pricing → · Get the founding rate →